Capricor Therapeutics Net Profit Margin Growth & History (CAPR)
Capricor Therapeutics's net profit margin was −181.71% for fiscal 2024.
View full Capricor Therapeutics company overviewCapricor Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −181.71% | −93.19 pp |
| 2023 | 2023-12-31 | −88.52% | +1048.85 pp |
| 2022 | 2022-12-31 | −1,137.37% | +7038.50 pp |
| 2021 | 2021-12-31 | −8,175.86% | −3773.92 pp |
| 2020 | 2020-12-31 | −4,401.94% | −3641.58 pp |
| 2019 | 2019-12-31 | −760.36% | +148.55 pp |
| 2018 | 2018-12-31 | −908.91% | −1000.10 pp |
| 2017 | 2017-12-31 | 91.19% | +561.52 pp |
| 2016 | 2016-12-31 | −470.33% | −237.31 pp |
| 2015 | 2015-12-31 | −233.02% | −103.15 pp |
| 2014 | 2014-12-31 | −129.87% | +1637.09 pp |
| 2013 | 2013-12-31 | −1,766.96% | −707.49 pp |
| 2012 | 2012-12-31 | −1,059.47% | −974.61 pp |
| 2011 | 2011-12-31 | −84.85% | — |
Capricor Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | −63.94% | −57.63 pp |
| Q3 2024 | 2024-09-30 | −555.20% | −451.89 pp |
| Q2 2024 | 2024-06-30 | −276.97% | −88.93 pp |
| Q1 2024 | 2024-03-31 | −199.60% | +60.50 pp |
| Q4 2023 | 2023-12-31 | −6.30% | +290.65 pp |
| Q3 2023 | 2023-09-30 | −103.31% | +296.99 pp |
| Q2 2023 | 2023-06-30 | −188.04% | — |
| Q1 2023 | 2023-03-31 | −260.10% | — |
| Q4 2022 | 2022-12-31 | −296.96% | — |
| Q3 2022 | 2022-09-30 | −400.30% | — |
| Q2 2021 | 2021-06-30 | −2,326.65% | +4660.67 pp |
| Q1 2021 | 2021-03-31 | −12,622.31% | −11499.59 pp |
| Q4 2020 | 2020-12-31 | −7,224.51% | −6562.90 pp |
| Q3 2020 | 2020-09-30 | −23,187.59% | −22056.75 pp |
| Q2 2020 | 2020-06-30 | −6,987.31% | −6488.61 pp |
| Q1 2020 | 2020-03-31 | −1,122.72% | −29.75 pp |
| Q4 2019 | 2019-12-31 | −661.60% | −158.60 pp |
| Q3 2019 | 2019-09-30 | −1,130.84% | +755.66 pp |
| Q2 2019 | 2019-06-30 | −498.71% | +522.08 pp |
| Q1 2019 | 2019-03-31 | −1,092.97% | −175.24 pp |
| Q4 2018 | 2018-12-31 | −503.00% | −1564.35 pp |
| Q3 2018 | 2018-09-30 | −1,886.50% | −1013.46 pp |
| Q2 2018 | 2018-06-30 | −1,020.78% | +88.99 pp |
| Q1 2018 | 2018-03-31 | −917.73% | −501.45 pp |
| Q4 2017 | 2017-12-31 | 1,061.35% | +1559.53 pp |
| Q3 2017 | 2017-09-30 | −873.04% | −158.86 pp |
| Q2 2017 | 2017-06-30 | −1,109.77% | −694.76 pp |
| Q1 2017 | 2017-03-31 | −416.28% | −65.17 pp |
| Q4 2016 | 2016-12-31 | −498.18% | −200.33 pp |
| Q3 2016 | 2016-09-30 | −714.19% | −492.73 pp |
| Q2 2016 | 2016-06-30 | −415.01% | −173.18 pp |
| Q1 2016 | 2016-03-31 | −351.11% | −156.69 pp |
| Q4 2015 | 2015-12-31 | −297.86% | −160.33 pp |
| Q3 2015 | 2015-09-30 | −221.46% | −102.83 pp |
| Q2 2015 | 2015-06-30 | −241.83% | −94.57 pp |
| Q1 2015 | 2015-03-31 | −194.43% | −78.21 pp |
| Q4 2014 | 2014-12-31 | −137.53% | — |
| Q3 2014 | 2014-09-30 | −118.63% | +1802.54 pp |
| Q2 2014 | 2014-06-30 | −147.26% | +710.00 pp |
| Q1 2014 | 2014-03-31 | −116.22% | +491.23 pp |
| Q3 2013 | 2013-09-30 | −1,921.17% | — |
| Q2 2013 | 2013-06-30 | −857.26% | — |
| Q1 2013 | 2013-03-31 | −607.44% | −212.62 pp |
| Q1 2012 | 2012-03-31 | −394.82% | — |
| Q3 2011 | 2011-09-30 | −140.72% | — |
| Q2 2011 | 2011-06-30 | −254.49% | — |
Capricor Therapeutics net profit margin trends
Over the last five fiscal years, Capricor Therapeutics's net profit margin increased from −760.36% to −181.71%, a change of +578.65 percentage points. The latest reported quarter, Q4 2024, shows −63.94%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Capricor Therapeutics source filings ↗